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Abstract
Introduction Seven SNPs in five genomic loci were recently
found to confer a mildly increased risk of breast cancer.
Methods We have investigated the correlations between
disease characteristics and the patient genotypes of these
SNPs in an unselected prospective cohort of 1,267 consecutive
patients with primary breast cancer.
Results Heterozygote carriers and minor allele homozygote
carriers for SNP rs889312 in the MAP3K1 gene were less likely
to be lymph node positive at breast cancer diagnosis (P  =
0.044) relative to major allele homozygote carriers.
Heterozygote carriers and minor allele homozygote carriers for
SNP rs3803662 near the TNCR9 gene were more likely to be
diagnosed before the age of 60 years (P = 0.025) relative to
major allele homozygote carriers. We also noted a correlation
between the number of minor alleles of rs2981582 in FGFR2
and the average number of first-degree and second-degree
relatives with breast cancer and/or ovarian cancer (P = 0.05). All
other disease characteristics, including tumour size and grade,
and oestrogen or progesterone receptor status, were not
significantly associated with any of these variants.
Conclusion Some recently discovered genomic variants
associated with a mildly increased risk of breast cancer are also
associated with breast cancer characteristics or family history of
breast cancer and ovarian cancer. These findings provide
interesting new clues for further research on these low-risk
susceptibility alleles.
Introduction
Breast cancer is the most commonly occurring cancer among
women in the industrialized world, where it accounts for 22%
of all female cancers. Many breast cancer risk factors have
been identified but a positive family history remains among the
most important, with first-degree relatives of patients having an
approximately twofold elevated risk [1]. Several genes are
known to confer increased susceptibility to breast cancer [2],
including BRCA1 and BRCA2, but it has been estimated that
they explain only about 25% of the familial risk [3,4] and less
than 5% of the total breast cancer incidence. This is because
even though the risks conferred by mutations in BRCA1 and
BRCA2 are substantial, the frequencies of these mutations in
the population are very rare.
BCAC = Breast Cancer Association Consortium; ORIGO = Dutch hospital-based cohort of breast cancer patients; SNP = single nucleotide poly-
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In contrast, twin studies and studies of the incidence of con-
tralateral breast cancer have suggested that the proportion of
breast cancer that can be attributed to genetic factors may be
as high as 30% [5,6], implying that there are still breast cancer
susceptibility genes to be identified. Linkage studies in multi-
ple case families, however, have failed to identify further major
breast cancer genes [7].
This failure has strengthened the idea that a large proportion
of the familial risk of breast cancer is due to multiple loci, each
conferring a small risk [4]. Variants in CHEK2 [8], BRIP1 [9]
and PALB2 [10] fall into this category, but their population fre-
quencies are very low, and thus so is their overall contribution
to breast cancer incidence.
A recent large-scale, genome-wide scan for associations [11]
has identified five new loci, each containing one or two SNPs
that are very strongly associated with breast cancer in several
populations of diverse ethnicity. Four of these contain plausi-
ble causative genes (FGFR2, TNRC9, MAP3K1 and LSP1).
The per-allele odds ratios conferred by these variants ranged
from 1.07 to 1.26, with minor allele frequencies ranging from
28% to 46%. These risks are too low to be useful in genetic
predictive testing, but substantial proportions of breast cancer
patients are heterozygous or are homozygous for these
variants.
It is therefore interesting to investigate whether the identified
variants in these loci are associated with particular disease
characteristics, such as tumour grade and stage. Breast
tumours arising in carriers of BRCA1 mutations have been
shown to have a distinct phenotype [12,13], and patients car-
rying the 1100delC mutation in CHEK2 are at higher risk of
developing secondary disease [14,15]. In a prospective hos-
pital-based series of 1,267 incident breast cancer cases in the
southwest of The Netherlands, we compared, in a case-only
design, the genotypes at seven SNPs in the five newly identi-
fied low-risk loci with tumour and disease characteristics and
other breast cancer risk factors.
Materials and methods
Patients
During the period October 1996–December 2005, patients
who were diagnosed with a primary breast tumour were con-
secutively recruited from two academic hospitals (Leiden Uni-
versity Medical Center, Leiden and the Erasmus MC–Daniel
den Hoed Cancer Center, Rotterdam) in the southwest of The
Netherlands, irrespective of their family history. Patients over
the age of 70 years at the time of diagnosis were excluded
from the Erasmus MC–Daniel den Hoed Cancer Center
cohort to enrich their population for hereditary factors. One
hundred and three patients who were invited to join this study
declined to participate. The final Dutch hospital-based
ORIGO cohort of breast cancer patients consisted of 1,359
patients, of which 1,207 were diagnosed with invasive breast
cancer and 152 with carcinoma in situ.
After giving informed consent, patients filled in a questionnaire
on breast cancer risk factors (age at menarche and age at first
pregnancy, total number of pregnancies and duration of
breastfeeding, age at menopause, use of oral contraceptives,
alcohol use) and on family cancer history. Questionnaires were
not returned by 90 of the 1,359 patients (6.6%). A further two
patients were excluded from the analysis because of poor gen-
otyping quality, so that for a total number of 1,267 patients in
the ORIGO cohort both genotyping information and informa-
tion on personal breast cancer risk factors were known. This
final cohort consisted of 549 patients from the Leiden Univer-
sity Medical Center and 718 patients from the Erasmus MC–
Daniel den Hoed Cancer Center.
Age at diagnosis and body mass index were recorded from the
hospital records, and information on tumour histology, includ-
ing tumour size and lymph node status, and on oestrogen
receptor, progesterone receptor and HER2/neu status, was
retrieved from the pathology reports. Because of the small
number of patients for whom HER2/neu status was known (n
= 76), this characteristic was excluded from our statistical
analysis. A blood sample was collected from each patient and
DNA was isolated. During the ongoing follow-up, local, locore-
gional and distant recurrence of disease and death were
recorded.
To assess allele frequencies in the general population, we
genotyped 378 healthy blood donors from the southwest
region of The Netherlands (93 females, 285 males), and 234
healthy spouses of family members of families with multiple
breast cancer cases (169 males and 65 females) [16].
The Medical Ethical Review Boards of the involved centres
approved the study protocol, under the condition that written
informed consent was obtained from the patients.
Genotyping
With the ORIGO cohort we participated in the third stage of
the Breast Cancer Association Consortium (BCAC) genome-
wide association study, in which 30 of the most significant
SNPs from stage 2 were genotyped in 22 case–control stud-
ies [11]. In total these studies comprised 21,668 cases of
invasive breast cancer, 967 cases of carcinoma in situ and
20,973 control cases [11]. A 31st SNP was added later as a
result of fine-scale mapping of the TNRC9 locus. Details on
the genotyping methods can be found in the article by Easton
and colleagues [11]. In the ORIGO cohort, genotypes were
successfully called in at least 95% of the samples for all SNPs
– except for SNP rs8051542, for which successful genotype
calling was present in 89.5% of all samples.Available online http://breast-cancer-research.com/content/9/6/R78
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Statistical analysis
The prevalence of the minor allele of each SNP in the ORIGO
population was compared with the prevalence in the control
population using chi-square tests. The odds ratios were calcu-
lated using regression analysis.
The combined effect of SNP rs2981582 and each one of the
other six SNPs was explored pairwise in the ORIGO cohort.
Patients were stratified into nine groups according to their
genotype at rs2981582 and at the other SNP, and the odds
ratios of each subgroup were calculated using regression
analysis – the group of patients being homozygous for the
major alleles of both SNPs serving as reference category
(odds ratio = 1.0). Analysis of three or more SNPs at the same
time resulted in subgroups too small for statistical analysis.
In the BCAC study, the odds ratios for heterozygous and
homozygous carriers of the rare allele of each SNP were in
agreement with a codominant model. We therefore analysed
the effect of each SNP on disease characteristics by classify-
ing the patients from our ORIGO cohort into three groups:
patients homozygous for the major allele (wt/wt), patients het-
erozygous for the wildtype and mutated or minor allele (wt/mt),
and patients homozygous for the minor allele (mt/mt). Since
the group of patients homozygous for the minor allele was
often small, associations between the SNP status and the dis-
ease characteristics were also studied comparing the group of
patients homozygous for the major allele with those carrying
one or two minor alleles.
Disease characteristics were compared between the three
patient groups using logistic regression for dichotomous vari-
ables, chi-square tests for categorical variables, and one-way
analyses of variance for continuous variables. For the analyses
comparing two patient groups, Pearson's correction was
applied to the chi-square tests and continuous variables were
compared using the Student t test.
P < 0.05 was considered statistically significant. P < 0.1 was
considered a possible trend that could be explored further in
larger study groups.
All analyses on the ORIGO cohort and its control group were
performed with SPSS version 11.0.1 (SPSS Inc., Chicago, IL,
USA).
Results
The characteristics of the 1,267 patients in the ORIGO cohort
are summarized in Table 1. The average age at diagnosis was
54.0 years, which is several years younger than the average for
all Dutch patients (61.3 years) [17]. This younger diagnosis
age is due to the fact that in one accrual hospital only patients
diagnosed before the age of 70 years were included. All other
disease characteristics are not significantly different from
population-based data.
The ORIGO cohort took part in a large three-phase, genome-
wide study conducted by the BCAC, which identified seven
SNPs to be significantly associated with breast cancer [11].
These SNPs map to five genomic loci, including the FGFR2
gene (SNP rs2981582) that encodes the fibroblast growth
factor receptor 2, the TNRC9  gene (rs12443621,
rs8051542, rs3803662), the MAP3K1 gene (rs889312) that
encodes mitogen-activated protein kinase kinase kinase 1, the
LSP1 gene (rs3817198) that codes for lymphocyte-specific
protein 1, and a gene-less linkage disequilibrium block of
~110 kb on 8q24 (rs13281615).
Table 2 presents these seven SNPs with the strengths of the
associations in the total BCAC study, as compared with those
in the ORIGO cohort alone. The ORIGO cohort and the con-
trol cohort were in Hardy–Weinberg equilibrium for each of
the seven SNPs investigated. Only the SNP in FGFR2
reached formal statistical significance in the ORIGO cohort (P
trend < 0.007), in the same direction as in the overall BCAC
study. The other SNPs did not reach statistical significance,
although the observed per-allele odds ratios were similar to
those obtained in the overall BCAC study, with the exception
of SNP rs889312.
An important issue to be resolved is whether women carrying
risk alleles at more than one of these five loci are at an even
greater risk of developing breast cancer than those carrying
only one risk allele, and whether there are epistatic interac-
tions. In an attempt to address this issue, we analysed the
combined effects of SNP rs2981582 in FGFR2 and each one
of the other six SNPS on breast cancer risk in our ORIGO
cohort (Additional file 1). A significant stepwise increase of the
odds ratio was observed in the ORIGO cohort, depending on
the combined number of minor alleles present for rs2981582
(FGFR2) and for rs3803662 (TNRC9) (P = 0.022; Table 3),
with an observed maximum odds ratio of 2.22.
The main objective of our current study was to investigate
associations between disease characteristics and the SNP
genotypes in the ORIGO cohort. Significant (P < 0.05) and
near-significant results (P < 0.10) are presented in Table 4
(see also Additional file 2).
In the ORIGO cohort, the minor allele of SNP rs2981582 in
FGFR2 was found to correlate with a positive family history of
breast cancer, defined as the ratio of the number of relatives
with breast cancer and/or ovarian cancer relative to the total
number of female relatives. This ratio, which corrects for differ-
ences in family size, was higher for carriers of one or two of the
minor alleles (P = 0.05). Nonsignificant trends for association
were observed for other definitions, such as the presence of at
least one first-degree or second-degree family member with
breast cancer, or with breast cancer and/or ovarian cancer.
Likewise, the minor allele of SNP rs3803662 in the TNRC9
locus also showed a nonsignificant trend with a larger numberBreast Cancer Research    Vol 9 No 6    Huijts et al.
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Table 1
Baseline characteristics of the Dutch hospital-based ORIGO cohort of breast cancer patients (n = 1267)
Variable Value
Age at diagnosis (years) (n = 1,254) 54 ± 11.2 (21–88)
Follow-up time (months) (n = 476) 64 ± 31 (3–126)
Body mass index (kg/m2) (n = 1,203) 25 ± 4 (16–45)
Sex (n = 1,267)
Female 1262 (99.6%)
Male 5 (0.4%)
Bilaterality of breast cancera (n = 1,265)
Bilateral 79 (6.2%)
Unilateral 1186 (93.8%)
Tumour characteristics
Bloom–Richardson grade (n = 964)
Grade I 175 (18.2%)
Grade II 399 (41.4%)
Grade III 390 (40.5%)
Clinical staging of cancer (UICC)b (n = 1,230)
Stage 0 (in situ) 144 (11.7%)
Stage 1 479 (38.9%)
Stage 2 526 (42.8%)
Stage 3 81 (6.6%)
Receptor status
Oestrogen receptor (n = 831)
Positive 597 (71.8%)
Negative 234 (28.2%)
Progesterone receptor (n = 683)
Positive 399 (58.4%)
Negative 284 (41.6%)
Human epidermal growth factor receptor 2 (HER2/neu) (n = 76)
Positive 14 (18.4%)
Negative 62 (81.6%)
Risk factors
Family historyc (n = 1,253)
Negative 753 (60.1%)
Positive 500 (39.9%)
Pregnancy (n = 1,179)
Ever 968 (82.1%)
Never 211 (17.9%)
Breastfeeding (n = 1,215)
Ever 693 (57%)
Never 522 (43%)
Breastfeeding duration (months) 5.21 ± 9.8 (0–121)
Data presented as the mean ± standard deviation (range) or number (% of total number). aWithin 6 months of first diagnosis. bInternational Union 
Against Cancer (UICC) stages, based on T classification and N classification, known in 1,230 patients. cFamily history is considered positive when 
at least one first-degree or second-degree relative also had breast cancer, irrespective of age at onset.Available online http://breast-cancer-research.com/content/9/6/R78
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of first-degree relatives with breast cancer (on average, 0.23
in major allele homozygous patients versus 0.28 and 0.31 for
heterozygous patients and minor allele homozygous patients,
respectively).
In our cohort, the minor allele of SNP rs3803662 in the
TNRC9 locus was associated with younger age at diagnosis,
reflected by an overrepresentation of carriers of one or two
minor alleles in the age groups between 40 years and 60 years
(Figure 1). The mean age at diagnosis was 54.3 years, 53.4
years and 52.5 years for the patients homozygous for the
major allele, for heterozygous patients and for patients
homozygous for the minor allele, respectively, but the differ-
ence between these values was not significant (P = 0.199).
Heterozygote carriers and minor allele homozygote carriers for
SNP rs889312 in the MAP3K1 gene were less likely to have
lymph-node-positive breast cancer at diagnosis (P = 0.044)
compared with major allele homozygote carriers. An opposite
but nonsignificant trend was observed for SNP rs3817198; a
slightly higher proportion of heterozygous patients and minor
allele homozygous patients had lymph-node-positive breast
cancer compared with major allele homozygous patients (P =
0.078).
In the ORIGO cohort, information on pregnancy and breast-
feeding was present for 1,179 patients. Of these, 690 patients
had provided breastfeeding for more than 1 month in total.
Although not reaching significance, homozygous carriers and
heterozygous carriers of the minor allele of SNP rs2981582
had breastfed for a longer period of time than homozygous
carriers of the major allele (5.8 months and 5.5 months versus
4.5 months, respectively). The same trend was seen in
homozygous carriers and heterozygous carriers of the minor
allele of rs3803662, who had breastfed for a longer period of
time than homozygous carriers of the major allele (6.4 months,
5.7 months and 4.9 months, respectively).
The tumours of heterozygous carriers or homozygous carriers
of the minor allele of SNP rs12443621, which is in strong link-
age disequilibrium with SNPs rs8051542 and rs3803662 in
the TNRC9 locus, were significantly more often negative for
the progesterone receptor (41.4% and 52.3% for the
heterozygous patients and for homozygous patients of the
Table 2
Minor allele frequencies, P values and per-allele odds ratios of the seven SNPs in the Breast Cancer Association Consortium 
(BCAC) study and in the Dutch hospital-based ORIGO cohort of breast cancer patients
SNP Minor allele frequency P trend Per-allele odds ratio
BCAC study ORIGO cohort BCAC study ORIGO cohort BCAC study ORIGO cohort
rs2981582 0.38 0.38 2.10-76 0.007 1.26 1.30
rs3803662 0.25 0.26 1.10-36 0.131 1.20 1.13
rs889312 0.28 0.31 7.10-20 0.727 1.13 1.03
rs12443621a 0.46 0.43 2.10-19 0.805 1.11 1.05
rs8051542a 0.44 0.48 1.10-12 0.494 1.09 0.96
rs13281615 0.40 0.39 5.10-12 0.277 1.08 1.10
rs3817198 0.30 0.30 3.10-9 0.529 1.07 1.06
aSNPs rs12443621 and rs8051542 were in linkage disequilibrium with SNP rs3803662.
Table 3
Combined odds ratios for the two most significant SNPs in the Dutch hospital-based ORIGO cohort of breast cancer patients
SNP rs2981582 in FGFR2 SNP rs3803662 near TNRC9
0 (wt/wt) 1 (wt/mt) 2 (mt/mt)
0 (wt/wt) 1.00 1.25 (0.87–1.78) 1.12 (0.64–1.97)
1 (wt/mt) 1.28 (0.95–1.72) 1.48 (1.06–2.05) 1.90 (1.07–3.39)
2 (mt/mt) 1.76 (1.17–2.66) 2.22 (1.37–3.60) 1.35 (0.57–3.20)
The combined effect of SNPs rs2981582 and rs3803662 on breast cancer risk was studied in the ORIGO cohort. The observed odds ratios and 
their 95% confidence intervals are presented. wt/wt, patients homozygous for the wildtype allele; wt/mt, patients heterozygous for the wildtype 
and mutated or minor allele; mt/mt, patients homozygous for the mutated or minor allele. P value for overall differences = 0.022.Breast Cancer Research    Vol 9 No 6    Huijts et al.
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minor allele versus 38.2% in the homozygous patients for the
major allele, P = 0.048). The same trend was seen with SNPs
rs8051542 and rs3803662, but did not reach significance (P
= 0.3 and P = 0.69, respectively). No such associations were
observed for the oestrogen receptor status.
The minor allele of SNP rs12443621 near TNRC9 was also
significantly associated with a slightly lower body mass index
(P = 0.043). A similar lower body mass index was also seen in
carriers of the minor allele of nearby SNP rs3803662, but the
association was not significant (P = 0.680). SNP rs8051542,
in the same region, did not show the same trend and did not
reach significance.
Follow-up was updated in October 2006 for 476 patients
diagnosed in the Leiden University Medical Center Hospital,
with a mean follow-up period of 64 months, but no significant
associations were observed between overall survival and dis-
ease-free survival and any of the seven SNPs.
No differences were observed between the genotype groups
for any of the seven SNPs tested and the bilateral occurrence
of breast cancer, the Bloom–Richardson differentiation grade,
carcinoma in situ versus invasive cancer, the clinical breast
Table 4
Associations of SNPs with disease characteristics in the Dutch hospital-based ORIGO cohort of breast cancer patients
Patient or disease characteristics wt/wt wt/mt mt/mt P value, three groupsa P value, two groupsb
SNP rs2981582 (in FGFR2)
Family history
Positive for breast cancer (%) 36 40 45 0.089 0.095
Positive for breast cancer and/or ovarian cancer (%) 38 42 48 0.065 0.089
Average number of relatives with breast cancer or ovarian cancer 
divided by the total number of female relatives
0.067 0.071 0.089 0.05 0.193
Average duration of breastfeeding (months) 4.5 5.5 5.8 0.224 0.062
SNP rs3817198 (in LSP1)
Positive lymph-node status (%) 39 44 44 0.190 0.078
SNP rs889312 (near MAP3K1)
Positive lymph-node status (%) 45 40 36 0.090 0.044
SNP rs3803662 (near TNRC9)
Age at diagnosis <60 years (%)c 68 73 82 0.054 0.025
Family history
Average number of first-degree relatives with breast cancer 0.23 0.28 0.31 0.156 0.072
Average number of relatives with breast cancer divided by total 
number of female relatives
0.063 0.070 0.082 0.166 0.118
Average duration of breastfeeding (months) 4.9 5.7 6.4 0.206 0.097
wt/wt, patients homozygous for the wildtype allele; wt/mt, patients heterozygous for the wildtype and mutated or minor allele; mt/mt, patients 
homozygous for the mutated or minor allele. aComparing the three genotype groups separately. bA codominant model, comparing the group of 
homozygous patients for the wildtype allele with the combined group of heterozygous patients and patients homozygous for the minor allele. cSee 
also Figure 1.
Figure 1
Age at breast cancer diagnosis according to rs3803663 (TNRC9)  genotype in the ORIGO cohort Age at breast cancer diagnosis according to rs3803663 (TNRC9) 
genotype in the ORIGO cohort. The age at diagnosis in the Dutch hos-
pital-based ORIGO cohort of breast cancer patients is represented by 
four age categories: before the age of 40 years, between the ages of 
40 years and 50 years, between the ages of 50 years and 60 years, 
and above the age of 60 years. wt/wt, patients homozygous for the 
wildtype or major allele; wt/mt, patients heterozygous for the wildtype 
and mutated or minor allele; mt/mt, patients homozygous for the mutant 
or minor allele.Available online http://breast-cancer-research.com/content/9/6/R78
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cancer stage (International Union Against Cancer), age at first
pregnancy or the total number of pregnancies and total dura-
tion of pregnancies.
Discussion
Even though our ORIGO cohort is a hospital-based cohort,
the patient and tumour characteristics of the included patients
are very similar to those of a population-based breast cancer
cohort, with the exception of age at diagnosis [18-20]. The
percentage of patients with a positive family history for breast
cancer is not different from other breast cancer populations
[1,21].
In the ORIGO cohort, we first studied the association between
seven recently identified low-risk breast cancer susceptibility
alleles in five genomic regions and breast cancer risk in
general.
It is interesting to note that, although the ORIGO cohort con-
sists of only 1,359 cases, the per-allele odds ratios calculated
for the seven SNPs in the BCAC study and in the ORIGO
cohort are similar. Although the increase in breast cancer risk
inferred by the minor allele of each of these SNPs is only small,
the attributable risks are high due to the high frequency of the
minor allele in the population.
To investigate the combined effects of these SNPs on breast
cancer risk, we calculated the odds ratios of the combination
of the most important SNP (rs2981582 in FGFR2) with one
other SNP. We found significantly higher odds ratios when
genotypes at SNP rs2981582 (FGFR2) and at SNP
rs3803662 (TNRC9) were combined, with magnitudes in
keeping with a simple multiplicative model. If confirmed in
larger cohorts, this statistical interaction could provide clues
about the biological functions of the involved proteins in breast
cancer development.
In the present study, we proceeded by focusing on the asso-
ciations between patient characteristics and histopathological
characteristics and genotypes at the seven SNPs in our
ORIGO cohort. Although this cohort is relatively small, it is
also homogeneous and extensively characterized, allowing an
elaborate first exploration of the possible associations
between the SNPs and disease characteristics.
In the BCAC study, SNP rs2981582 in FGFR2 was most
strongly associated with breast cancer [11], an association
that was replicated in three independent postmenopausal
breast cancer cohorts [22]. In the ORIGO cohort, rs2981582
genotypes correlated with a positive family history of breast
cancer and/or ovarian cancer, although this was significant
only when the ratio of the number of relatives with breast can-
cer and/or ovarian cancer relative to the total number of female
relatives was compared. The BCAC study also found an asso-
ciation between this SNP and women with a first-degree rela-
tive with breast cancer. Our results thus suggest that this
association may also include relatives with ovarian cancer.
Expression of FGFR2 subtype IIIb has been implicated to be
upregulated in up to 80% of epithelial ovarian cancers [23,24].
Although the functionality of rs2981582 with regard to an
increased cancer risk is as yet unresolved, it has been specu-
lated that it is mediated through regulation of FGFR2 expres-
sion [11].
Two other SNPs (rs3803662 and rs13281615) were also
linked to family history in the BCAC study, and this was also
noted for rs3803662 in the ORIGO cohort, although not sig-
nificantly (P = 0.072). This effect was observed only for breast
cancer family history, and was lost when adding ovarian can-
cer cases to the analysis. The association between
rs13281615 and family history was not observed in the
ORIGO cohort.
We did not confirm the association between rs3803662 in
TNRC9, the second most significant SNP in the BCAC study,
and breast cancer risk in our cohort. However, we did observe
that heterozygote carriers and minor allele homozygote carri-
ers for this SNP had a higher probability of being diagnosed
with a breast tumour before age 60 years than major allele
homozygote carriers. This effect is to be expected for suscep-
tibility loci, although it was not seen for other SNPs in our
cohort, and only a trend was observed in the BCAC study
[11].
It is possible that a low-risk allele not only influences the
chance of developing breast cancer but also influences
tumour characteristics such as invasiveness. In our cohort we
found that patients carrying one or two minor alleles of
rs889312 in MAP3K1 were less likely to have lymph-node-
positive breast cancer, suggesting that the invasive potential
of the tumour in these patients might be lower. A trend for an
opposite effect was observed for rs3817198 in LSP1. There
was, however, no significant effect of either one of these SNPs
on overall survival or disease-free survival, but this may be due
to the relatively small sample size and the short period of
follow-up.
A prolonged period of breastfeeding is a known protective fac-
tor against breast cancer [25]. Carriers of one or two minor
alleles of SNPs rs2981582 and rs3803662 breastfed for a
longer period of time, but developed breast cancer nonethe-
less, suggesting that the protective effect of breastfeeding
might have been counteracted by the presence of the minor
allele of either SNP.
We have shown previously that the CHEK2*1100delC germ-
line mutation was more prevalent among patients with a posi-
tive oestrogen receptor status in the ORIGO cohort [26]. A
similar finding was made for SNP rs3803662, in that the risk
of this allele was strongly confined to patients with oestrogen-Breast Cancer Research    Vol 9 No 6    Huijts et al.
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receptor-positive tumours [27]. We examined this association
for the seven SNPs in our cohort but did not find any effect
with oestrogen receptor status for any, and only a few weak
associations were found with progesterone receptor status. It
is conceivable that the risks conferred by these alleles are
expressed only in receptor-positive or receptor-negative sub-
groups of patients, but these differences in risk are probably
too small to be detected in our cohort. With the current cohort
of 831 patients with known oestrogen receptor status, we had
only a statistical power of 59% to detect a difference in oes-
trogen receptor status of 10%.
We did not observe any association between genotypes at the
seven SNPs and a variety of other clinical parameters, includ-
ing the bilateral occurrence of breast cancer, the Bloom–Rich-
ardson grade, the clinical International Union Against Cancer
stage, age at first pregnancy or the total number of pregnan-
cies and duration of pregnancies.
Conclusion
In summary, several of the seven recently identified common
genetic variants that predispose to breast cancer are associ-
ated with certain clinical characteristics, such as family history,
nodal involvement, and age at diagnosis, in a Dutch cohort of
breast cancer patients. These findings should be regarded
with caution, given the relatively small size of the ORIGO
cohort. The clinical implications of these findings are at
present therefore undetermined. These results do, however,
provide interesting new clues for further association studies in
larger patient cohorts as well as for further research aimed at
elucidating the causal relationship of the SNPs with breast
cancer.
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